Tenacissoside I
CAS: 191729-44-9
Rif. 3D-FT74349
| 2mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione |
Informazioni sul prodotto
Nome:
Tenacissoside I
Sinonimi:
- (3β,5α,11α,12β,14β,17α)-12-Acetoxy-3-{[2,6-dideoxy-4-O-(6-deoxy-3-O-methyl-β-D-allopyranosyl)-3-O-methyl-β-D-arabino-hexopyranosyl]oxy}-20-oxo-8,14-epoxypregnan-11-yl benzoate
- Pregnan-20-one, 12-(acetyloxy)-11-(benzoyloxy)-3-[[2,6-dideoxy-4-O-(6-deoxy-3-O-methyl-β-D-allopyranosyl)-3-O-methyl-β-D-arabino-hexopyranosyl]oxy]-8,14-epoxy-, (3β,5α,11α,12β,14be ta,17α)-
- (3beta,5alpha,11alpha,12beta,14beta,17alpha)-12-(Acetyloxy)-11-(benzoyloxy)-3-[[2,6-dideoxy-4-O-(6-deoxy-3-O-methyl-beta-D-allopyranosyl)-3-O-methyl-beta-D-arabino-hexopyranosyl]oxy]-8,14-epoxypregnan-20-one
- Tenacissimoside B
Descrizione:
Tenacissoside I is a polyhydroxylated triterpene compound derived from the Chinese herb, Tenacissus. It has been shown to have an anticancer activity by binding to epidermal growth factor receptor and blocking the downstream signaling pathway. Tenacissoside I has also been found to inhibit glucose uptake in human liver cells. This drug is then metabolized into tenacissoside II and tenacissoside III, which are also active compounds. Tenacissoside I inhibits protein synthesis by competing with insulin for its receptor on the surface of cells, which results in a decreased glucose uptake.
Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:
Proprietà chimiche
Purezza:
Min. 95%
MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:
